newsfilter
← Latest News
GlobeNewswire·

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028

SPL028 is the Company's injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of